Cyclacel Pharmaceuticals Valuation

CYCC Stock  USD 0.32  0.02  6.67%   
Cyclacel Pharmaceuticals seems to be overvalued based on Macroaxis valuation methodology. Our model approximates the value of Cyclacel Pharmaceuticals from analyzing the firm fundamentals such as return on equity of -8.07, and Operating Margin of (217.70) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Cyclacel Pharmaceuticals' valuation include:
Price Book
2.0157
Enterprise Value
62.9 M
Enterprise Value Ebitda
0.0179
Price Sales
890.3135
Enterprise Value Revenue
850.016
Overvalued
Today
0.32
Please note that Cyclacel Pharmaceuticals' price fluctuation is out of control at this time. Calculation of the real value of Cyclacel Pharmaceuticals is based on 3 months time horizon. Increasing Cyclacel Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Cyclacel Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cyclacel Stock. However, Cyclacel Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  0.32 Real  0.29 Target  12.25 Hype  0.32 Naive  0.33
The real value of Cyclacel Stock, also known as its intrinsic value, is the underlying worth of Cyclacel Pharmaceuticals Company, which is reflected in its stock price. It is based on Cyclacel Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Cyclacel Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
0.29
Real Value
5.97
Upside
Estimating the potential upside or downside of Cyclacel Pharmaceuticals helps investors to forecast how Cyclacel stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cyclacel Pharmaceuticals more accurately as focusing exclusively on Cyclacel Pharmaceuticals' fundamentals will not take into account other important factors:
Earnings
Estimates (0)
LowProjectedHigh
0.000.000.00
Details
Hype
Prediction
LowEstimatedHigh
0.020.326.00
Details
Naive
Forecast
LowNext ValueHigh
0.010.336.01
Details
1 Analysts
Consensus
LowTarget PriceHigh
11.1512.2513.60
Details
Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Cyclacel Pharmaceuticals' intrinsic value based on its ongoing forecasts of Cyclacel Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Cyclacel Pharmaceuticals' closest peers. If more than one evaluation category is relevant for Cyclacel Pharmaceuticals we suggest using both methods to arrive at a better estimate.

Cyclacel Pharmaceuticals Cash

3.69 Million

Cyclacel Valuation Trend

Comparing Cyclacel Pharmaceuticals' enterprise value against its market capitalization is a good way to estimate the value of Cyclacel Pharmaceuticals uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.

Cyclacel Pharmaceuticals Total Value Analysis

Cyclacel Pharmaceuticals is currently forecasted to have valuation of 62.9 M with market capitalization of 65.88 M, debt of 37 K, and cash on hands of 29.08 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Cyclacel Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company
  Takeover PriceMarket CapDebt ObligationsCash
62.9 M
65.88 M
37 K
29.08 M

Cyclacel Pharmaceuticals Investor Information

About 95.0% of the company shares are held by company insiders. The company recorded a loss per share of 27.4. Cyclacel Pharmaceuticals last dividend was issued on the 15th of April 2020. The entity had 1:15 split on the 18th of December 2023. Based on the key indicators related to Cyclacel Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Cyclacel Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.

Cyclacel Pharmaceuticals Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cyclacel Pharmaceuticals has an asset utilization ratio of 4.77 percent. This indicates that the Company is making $0.0477 for each dollar of assets. An increasing asset utilization means that Cyclacel Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Cyclacel Pharmaceuticals Ownership Allocation

Cyclacel Pharmaceuticals holds a total of 205.88 Million outstanding shares. Cyclacel Pharmaceuticals shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 94.58 percent of Cyclacel Pharmaceuticals outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Cyclacel Pharmaceuticals Profitability Analysis

The company reported the previous year's revenue of 420 K. Net Loss for the year was (22.55 M) with profit before overhead, payroll, taxes, and interest of 74 K.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Cyclacel Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Cyclacel Pharmaceuticals and how it compares across the competition.

About Cyclacel Pharmaceuticals Valuation

The stock valuation mechanism determines Cyclacel Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of Cyclacel Pharmaceuticals. We calculate exposure to Cyclacel Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cyclacel Pharmaceuticals's related companies.
Last ReportedProjected for Next Year
Gross Profit483 K507.1 K
Pretax Profit Margin(54.75)(57.49)
Operating Profit Margin(54.54)(57.27)
Net Loss(48.33)(50.75)
Gross Profit Margin(25.06)(26.32)

Cyclacel Pharmaceuticals Growth Indicators

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
Common Stock Shares Outstanding850.8 K

Cyclacel Pharmaceuticals Current Valuation Indicators

Valuation refers to the process of determining the present value of Cyclacel Pharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Cyclacel we look at many different elements of the entity such as Cyclacel's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Cyclacel Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Cyclacel Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Cyclacel Pharmaceuticals' worth.

Complementary Tools for Cyclacel Stock analysis

When running Cyclacel Pharmaceuticals' price analysis, check to measure Cyclacel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclacel Pharmaceuticals is operating at the current time. Most of Cyclacel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cyclacel Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclacel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cyclacel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Commodity Directory
Find actively traded commodities issued by global exchanges